全球人源化小鼠模型市場規模（按類型、應用、最終用戶、地區、範圍和預測）

人源化小鼠模型的市場規模及預測

人源化小鼠模型市場規模預計在2024 年將達到1.2477 億美元，到2031 年將達到2.4226 億美元，在2024-2031 年預測期內的複合年增長率為9.54%。 。人源化小鼠模型是一種經過基因編輯的實驗室小鼠，包含人類基因、器官甚至免疫系統。科學家培育小鼠是為了更好地瞭解人類疾病並在體內測試潛在的治療方法。這些老鼠具有類似人類的特徵，因此比傳統老鼠更能有效複製疾病在人體中的進展。它們是生物醫學研究中必不可少的工具，具有廣泛的應用，有助於瞭解人類生物學和疾病。這些小鼠經過基因改造，攜帶人類基因、組織和細胞，使其成為研究人類特定體內生物過程的理想選擇。人源化小鼠模型主要用於藥物研究和測試。

人源化小鼠模型預計將在未來的生物醫學研究中發揮重要作用，特別是在藥物開發、免疫學和個人化醫療方面。人源化小鼠模型經過基因改造，擁有人類基因、器官和免疫細胞，是研究人類疾病和在受控環境中測試潛在治療方法的理想選擇。

人源化小鼠模型的全球市場動態

主要市場推動因素

個人化醫療的進展：

個人化醫療的興起是人源化小鼠模型業務的主要動力。個人化醫療尋求根據個別患者的基因組成客製化治療方案，人性化小鼠模型在這方面非常有用。這些模型經過設計，具有類似人類的免疫系統和其他人類基因，使研究人員能夠研究人類特有的疾病以及不同的治療方法在不同遺傳背景下的作用。

慢性病盛行率增加：

慢性病的發生率不斷上升，推動了對人性化小鼠模型的需求。這些模型比標準動物模型更準確地描述人類疾病狀態，而標準動物模型通常無法充分模擬人類生理學。例如，在癌症研究中，可以將人類腫瘤植入人源化小鼠，以便在受控環境下研究腫瘤的生長、轉移和對藥物的反應。

基因工程的技術進步：

基因工程技術的發展大大提高了人源化小鼠的生產和實用性。CRISPR/Cas9 技術使基因編輯變得更容易、更精確，使研究人員能夠開發出更接近人類生物學的模型。這些技術進步使得更為複雜和精確的人源化小鼠的開發成為可能，這對於研究複雜的人類疾病、藥物反應和免疫系統功能至關重要。

主要課題

基因工程的複雜性

開發人性化小鼠模型是一個耗時且複雜的過程。這些模型需要將人類基因、器官和免疫細胞引入小鼠體內，這需要複雜的基因工程程序。將人類元素插入小鼠基因組並確保其正常運作的過程非常困難。

壽命有限和繁殖問題：

人源化小鼠有較大的問題，包括壽命短、繁殖困難。人類基因和細胞的整合往往會導致免疫系統減弱和其他健康問題，使人們更容易生病並縮短壽命。

人性化不完全

另一個問題是人源化小鼠模型並不總是完全代表人類生物學。儘管它們可以模仿人類免疫反應和疾病過程的特徵，但它們本質上仍然屬於小鼠，在複製人類生理學方面有其限制。

主要趨勢：

基因工程的進展

一個值得注意的趨勢是，基因工程技術的重大進展使得建構更精確、更複雜的人源化小鼠模型成為可能。包括 CRISPR-Cas9 在內的基因編輯技術現在允許科學家精確修改小鼠基因組，以包括人類基因、細胞、器官甚至整個人類免疫系統。

在免疫腫瘤學研究的應用日益廣泛

人源化小鼠模型在免疫腫瘤學中變得越來越重要，該領域研究如何利用免疫系統對抗癌症。這些模型對於評估免疫療法（增強人體對癌細胞的免疫反應的藥物）的有效性特別有用。

擴大傳染病研究

另一個趨勢是人源化小鼠模型在傳染病研究中的應用越來越多，特別是在研究人類特異性傳染病，如愛滋病毒、肝炎以及最近的 COVID-19。這些模型對於瞭解病毒如何與人類細胞和免疫系統相互作用非常重要，因為典型的動物模型很難模擬這些相互作用。

目錄

第1章 全球人源化小鼠模型市場介紹

• 市場概況
• 調查範圍
• 先決條件

第 2 章執行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

• 數據挖掘
• 驗證
• 一次資料
• 數據源列表

第4章 全球人源化小鼠模型市場展望

• 概述
• 市場動態
  • 促進因素
  • 阻礙因素
  • 機會
• 波特的五力模型
• 價值鏈分析

第5章全球人源化小鼠模型市場依類型劃分

• 概述
• 基因人源化小鼠模型
• 基於細胞的人源化小鼠模型
  • CD34人類源化小鼠模型（Hu-CD34）
  • PBMC人源化小鼠模型
  • BLT人源化小鼠模型

第6章全球人源化小鼠模型市場（依應用）

• 概述
• 腫瘤學
• 免疫學/傳染病
• 神經科學
• 毒理學
• 造血
• 其他

第7章全球人源化小鼠模型市場依最終用戶劃分

• 概述
• 製藥和生物技術公司
• 合同研究所
• 學術/研究機構

第8章全球人源化小鼠模型市場（按地區）

• 概述
• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 亞太其他地區
• 世界其他地區
  • 拉丁美洲
  • 中東/非洲

第9章全球人源化小鼠模型市場競爭格局

• 概述
• 企業市佔率
• 供應商情況
• 主要發展策略

第10章 公司簡介

• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Horizon Discovery Group PLC
• Genoway S.A.
• Harbour Antibodies Bv（A Subsidiary of Harbour Biomed）
• Humurine Technologies
• Vitalstar Biotechnology Co., Ltd.
• Ingenious Targeting Laboratory
• Axenis S.A.S
• Trans Genic, Inc.

第 11 章 附錄

• 相關報導

Humanized Mouse Model Market Size And Forecast

Humanized Mouse Model Market size was valued at USD 124.77 Million in 2024 and is projected to reach USD 242.26 Million by 2031 , growing at a CAGR of 9.54% from 2024 to 2031. A humanized mouse model is a sort of laboratory mouse that has been genetically edited to contain human genes, organs, and even an immune system. Scientists develop these mice to better understand human ailments and test potential remedies in a living organism. Since these mice have human-like traits, they can more effectively replicate how a sickness might progress in a human body than conventional mice. These are essential tools in biomedical research, with a wide range of applications that help us understand human biology and illness. These mice are genetically modified to carry human genes, tissues, or cells, making them ideal for investigating human-specific biological processes in living organisms. Humanized mouse models are mostly used in medication research and testing.

Humanized mouse models are predicted to play an important role in future biomedical research, particularly in drug development, immunology, and personalized medicine. Humanized mouse models are genetically modified to carry human genes, organs, or immune cells making them ideal for studying human diseases and testing potential treatments in a controlled setting.

Global Humanized Mouse Model Market Dynamics

The key market dynamics that are shaping the global humanized mouse model market include:

Key Market Drivers:

Advances in Personalized Medicine:

The rise of personalized medicine is a major driver of the humanized mouse model business. Personalized medicine seeks to customize therapies for individual patients based on their genetic makeup, and humanized mouse models are extremely useful in this setting. These models which are designed to have human-like immune systems or other human genes, enable researchers to investigate human-specific diseases and explore how different treatments might function on diverse genetic backgrounds.

Increasing Prevalence of Chronic Diseases:

Chronic disease prevalence is increasing which is fuelling demand for humanized mouse models. These models offer a more accurate picture of human disease states than standard animal models which frequently fail to properly imitate human physiology. For example, in cancer research, humanized mice can be implanted with human tumors allowing scientists to examine tumor growth, metastasis, and response to medicines in a controlled setting.

Technological Advancements in Genetic Engineering:

Technological developments in genetic engineering have greatly improved the generation and utility of humanized mouse models. CRISPR/Cas9 techniques have made gene editing easier and more precise allowing researchers to develop models that closely match human biology. These technical advancements enable the development of more sophisticated and precise humanized mice which are critical for researching complex human diseases, medication reactions, and immune system functioning.

Key Challenges:

Complexity in Genetic Engineering

: Developing humanized mouse models is a time-consuming and complex procedure. These models necessitate the introduction of human genes, organs, or immune cells into mice which requires advanced genetic engineering procedures. The procedure of inserting human elements into the mouse genome and ensuring that they work properly is difficult.

Limited Lifespan and Reproduction Issues:

Humanized mice have a short lifetime and have difficulty reproducing which presents a big problem. The integration of human genes or cells frequently results in mice with weakened immune systems or other health issues rendering them more susceptible to disease and shortening their lifespan.

Incomplete Humanization

: Another issue is that humanized mouse models are frequently not completely representative of human biology. While they can mimic some features of human immune responses or disease processes, they are still fundamentally mice with limitations in their ability to duplicate human physiology.

Key Trends:

Advances in Genetic Engineering

: One noteworthy trend is the substantial advancement of genetic engineering techniques making it possible to construct more precise and complex humanized mouse models. CRISPR-Cas9 and other gene-editing technologies enable scientists to accurately alter mouse genomes to include human genes, cells, organs, and even entire human immune systems.

Increasing Use in Immuno-Oncology Research

. Humanized mouse models are becoming increasingly significant in immuno-oncology which studies how the immune system might be used to combat cancer. These models are especially useful for assessing the efficacy of immunotherapies which are medicines that increase the body's immunological response to cancer cells.

Expansion in Infectious Disease Research

: Another trend is the increased use of humanized mouse models in infectious disease research, particularly for researching human-specific infections such as HIV, hepatitis, and, most recently, COVID-19. These models are critical for learning how viruses interact with human cells and immune systems which is challenging to mimic using typical animal models.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Humanized Mouse Model Market Regional Analysis

Here is a more detailed regional analysis of the global humanized mouse model market:

North America:

North America dominates the humanized mouse model market owing to its strong research infrastructure and large investments in biomedical research. This supremacy is anticipated to persist in the next years, thanks to several major drivers. The first key driver of the humanized mouse model market in North America is the rising prevalence of chronic illnesses and cancer.

According to the Centers for Disease Control and Prevention (CDC), by 2021, 6 out of 10 adults in the United States will have a chronic disease with 4 out of 10 having two or more. Cancer, in particular, remains a major problem with the National Cancer Institute predicting 1,958,310 new cases in the United States by 2023.

The National Institutes of Health (NIH), the world's largest public supporter of biomedical research has a USD 45 Billion budget for fiscal year 2023 including a considerable amount dedicated to animal model research. Furthermore, the US Food and Drug Administration (FDA) has advocated for the use of humanized mouse models in preclinical investigations to better the translation of research findings into human applications.

Asia Pacific:

The Asia Pacific region is experiencing the quickest growth in the humanized mouse model market owing to significant advances in biomedical research and increased investments in healthcare infrastructure. This fast expansion is fueled by the region's booming pharmaceutical and biotechnology sectors as well as a growing emphasis on individualized medicine.

Chronic diseases such as cancer and autoimmune disorders have become increasingly common in the region. According to the World Health Organization, cancer is the biggest cause of death in Asia Pacific accounting for an estimated 8.8 million new cases and 5.5 million deaths in 2018. This has resulted in a greater desire for more efficient drug research and development processes with humanized mouse models playing an important role.

Asia Pacific's pharmaceutical and biotechnology industry have expanded rapidly. According to the Japan Pharmaceutical Manufacturers Association, the Japanese pharmaceutical market was valued at around 10.7 trillion yen (USD 98 Billion) in 2020 making it the world's third-largest market. This expansion has increased the demand for improved preclinical research tools, such as humanized mouse models.

Global Humanized Mouse Model Market: Segmentation Analysis

The Global Humanized Mouse Model Market is segmented based on Type, Application, End-User, and Geography.

Humanized Mouse Model Market, By Type

• Genetic Humanized Mouse Model
• Cell-Based Humanized Mouse Model
• CD34 Humanized Mouse Model (Hu-CD34)
• PBMC Humanized Mouse Model
• BLT Humanized Mouse Model

Based on the Type, the Global Humanized Mouse Model Market is bifurcated into Genetic Humanized Mouse Model, Cell-Based Humanized Mouse Model, CD34 Humanized Mouse Model (Hu-CD34), PBMC Humanized Mouse Model, and BLT Humanized Mouse Model. The genetic humanized mouse model is currently dominant in the global humanized mouse model market. This dominance is due to the model's advanced capability to replicate human-specific genes within the mouse genome providing researchers with a powerful tool to study human diseases, particularly in genetics and drug development. These models are essential for understanding gene function, and disease mechanisms, and for testing new therapies in a more human-relevant context.

Humanized Mouse Model Market, By Application

• Immunology and Infectious Diseases
• Neuroscience
• Oncology
• Haematopoiesis
• Toxicology
• Others

Based on the Application, the Global Humanized Mouse Model Market is bifurcated into Immunology and Infectious Diseases, Neuroscience, Oncology, Haematopoiesis, Toxicology, and Others. Oncology is the dominant application in the global humanized mouse model market. This dominance is driven by the critical role these models play in cancer research, particularly in the development of immunotherapies. Humanized mouse models are invaluable for studying human tumor growth and testing new cancer treatments, especially those targeting the immune system.

Humanized Mouse Model Market, By End-User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

Based on the End-User, the Global Humanized Mouse Model Market is bifurcated into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutions. Pharmaceutical & biotechnology companies are the dominant end users in the global humanized mouse model market. This dominance is driven by their extensive use of these models for drug discovery, development, and testing. Humanized mouse models are crucial for evaluating the efficacy and safety of new drugs, particularly those targeting complex human diseases and conditions. These companies rely on humanized mice to simulate human biological responses and predict how new therapies will perform in clinical trials.

Humanized Mouse Model Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Humanized Mouse Model Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global humanized mouse model market. This dominance is due to the region's advanced research infrastructure, high level of investment in biomedical research, and strong presence of major biotechnology and pharmaceutical companies. North America, particularly the United States leads in the development and adoption of innovative research technologies including humanized mouse models.

Key Players

• The "Global Humanized Mouse Model Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• The Jackson Laboratory, Taconic Biosciences, Inc., Horizon Discovery Group PLC, Genoway S.A., Harbour Antibodies Bv (A Subsidiary of Harbour Biomed), Humurine Technologies, Vitalstar Biotechnology Co., Ltd., Ingenious Targeting Laboratory, Axenis S.A.S, Trans Genic, Inc., Champions Oncology, Inc., Crown Bioscience, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Humanized Mouse Model Market Key Developments

• In January 2020, Taconic Biosciences, a global pioneer in developing drug discovery animal models, established a new model generation facility in Leverkusen, Germany. This complex, which replaces the previous Taconic facility in Cologne, Germany, houses model generation services.
• In January 2021, Champions Cancer, Inc., a leading worldwide cancer technology business that is redefining drug discovery and development with data-driven research techniques, today announced the expansion of their Lumin Bioinformatics SaaS program.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMANIZED MOUSE MODEL MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HUMANIZED MOUSE MODEL MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY TYPE

• 5.1 Overview
• 5.2 Genetic Humanized Mouse Model
• 5.3 Cell-Based Humanized Mouse Model
  • 5.3.1 CD34 Humanized Mouse Model (Hu-CD34)
  • 5.3.2 PBMC Humanized Mouse Model
  • 5.3.3 BLT Humanized Mouse Model

6 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Oncology
• 6.3 Immunology and infectious diseases
• 6.4 Neurosciences
• 6.5 Toxicology
• 6.6 Hematopoiesis
• 6.7 Others

7 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY END-USER

• 7.1 Overview
• 7.2 Pharmaceutical and Biotechnology Companies
• 7.3 Contract Research Organizations
• 7.4 Academic and Research Institutions

8 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL HUMANIZED MOUSE MODEL MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 The Jackson Laboratory
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Taconic Biosciences, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Horizon Discovery Group PLC
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Genoway S.A.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Humurine Technologies
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Vitalstar Biotechnology Co., Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ingenious Targeting Laboratory
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Axenis S.A.S
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Trans Genic, Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Reports